Statera BioPharma Company Information and Market Activity

Statera BioPharma is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for patients with rare and serious diseases. The company is headquartered in New Jersey.

Statera BioPharma was founded in 2019, making it a relatively new player in the biopharmaceutical industry. The company's mission is to bring transformative therapies to patients who need them most.

With a focus on rare diseases, Statera BioPharma is working to address significant unmet medical needs. Their research and development efforts are centered around creating novel treatments that can make a meaningful difference in patients' lives.

Worth a look: Sino Biopharmaceutical Limited

Statera BioPharma has been making waves in the biotech industry with its innovative approach to cancer treatment.

The company's lead product, ST-601, has shown promising results in clinical trials, with a significant reduction in tumor size in patients with advanced solid tumors. This is a major breakthrough, as traditional treatments often struggle to effectively target and shrink tumors.

Statera BioPharma's technology is based on a novel combination of chemotherapy and immunotherapy, which has shown to be effective in treating a range of cancer types. This approach has the potential to revolutionize cancer treatment and improve patient outcomes.

The company's focus on rare and aggressive cancers has also made a significant impact, with ST-601 demonstrating efficacy in treating patients with these types of cancers.

Statera Biopharma filed its Q1 Form 10-Q for the period ending March 31, 2022, with the SEC, while also working on the Q2 report.

The company secured an agreement with Silverback Capital to acquire $400,000 of a $15 million promissory note, converting it into an amended convertible note due May 1, 2024. This move aims to enhance Statera's financial standing.

Statera Biopharma has a strong financial history, closing a $5.7 million underwritten public offering in March 2022.

Worth a look: Jarrow March

Statera Biopharma received a notification letter from Nasdaq regarding its Form 10-Q filing on May 23, 2022.

The company was notified that it had failed to timely file its Form 10-Q for Q1 2022, prompting a review of its compliance with Nasdaq regulations.

This was not the first notification letter the company received, with previous letters sent on April 22, 2022, regarding its Form 10-K filing, and August 25, 2022, regarding its Form 10-Q filing.

Statera Biopharma has a history of struggling with timely filings, with the company receiving another notice of non-compliance on October 17, 2022, due to its failure to file its Form 10-Q for Q2 2022.

A different take: Coreweave S-1 Filing

Statera Biopharma announced a $5.7 million underwritten public offering in March 2022.

The offering was initially proposed on March 21, 2022, and was later priced on March 22, 2022.

This public offering helped the company raise $5.7 million.

You might enjoy: Credit Counseling Certificate Chapter 7 Free

Statera Biopharma has faced issues with regulatory compliance, receiving notices from Nasdaq regarding delinquent filings.

The company has not filed its Form 10-K for 2021 or the Forms 10-Q for the first two quarters of 2022, which has led to potential delisting from Nasdaq.

Statera has requested a hearing to seek an extension and demonstrate compliance, scheduled for October 6, 2022.

The company has also received additional notices of non-compliance due to its failure to timely file the Form 10-Q for Q2 2022 with the SEC.

On a similar theme: Q U a N T I T I E S

Statera Biopharma, a biopharmaceutical company, received a notification letter from Nasdaq regarding its Form 10-Q filing, stating that the company may face delisting due to non-compliance with filing requirements.

The company has not filed its Form 10-K for 2021 or the Forms 10-Q for the first two quarters of 2022, which triggered the delinquency notice. The hearing request was scheduled for October 6, 2022, to seek an extension and demonstrate compliance.

Statera Biopharma announced on September 1, 2022, that it may face delisting from Nasdaq due to non-compliance with filing requirements, which led to the hearing request. This was a concerning development for the company.

The hearing was scheduled for October 6, 2022, which gave the company an opportunity to address the delinquency and demonstrate its commitment to compliance.

Explore further: 2022 Russian Debt Default

Statera Biopharma has filed its Q1 Form 10-Q for the period ending March 31, 2022, with the SEC.

The company is also working on its Q2 report, demonstrating its commitment to transparency and compliance with regulatory requirements.

Statera Biopharma has secured an agreement with Silverback Capital to acquire $400,000 of a $15 million promissory note, converting it into an amended convertible note due May 1, 2024.

This move aims to enhance Statera's financial standing and improve its balance sheet.

CEO Michael Handley expressed confidence in complying with NASDAQ regulations and hopes for further note conversions to achieve this goal.

BF Borgers CPA PC is Statera Biopharma's independent registered public accounting firm. They were appointed to audit the company's financial statements for the year ended December 31, 2021. This move enhances transparency and reliability in Statera’s financial reporting. BF Borgers CPA PC is a reputable firm that specializes in public accounting.

Statera Biopharma is a biopharmaceutical company that creates next-generation immune therapies. They leverage a proprietary platform to develop treatments for various diseases, including autoimmune diseases, cancers, and emerging viruses.

Suggestion: What Is a Cpa

Statera BioPharma is a clinical-stage biopharmaceutical company.

Based in Fort Collins, Colorado, the company has a strong presence in the region.

Statera BioPharma is formerly known as Cytocom Inc., indicating a change in name and possibly direction.

Suggestion: Array BioPharma

Statera BioPharma is a clinical-stage biopharmaceutical company.

They're developing novel immunotherapies to target various conditions, including autoimmune diseases, neutropenia/anemia, emerging viruses, and cancers.

These treatments aim to rebalance the body's immune system and restore homeostasis.

Statera BioPharma is based in Fort Collins, Colorado.

Statera Biopharma received a notification letter from Nasdaq regarding its Form 10-K filing.

The letter was issued on April 22, 2022, and the company is a biopharmaceutical firm focused on creating next-generation immune therapies.

Statera Biopharma's stock is listed on the Nasdaq exchange under the ticker symbol STAB.

The company aims to create innovative immune therapies that focus on immune responses.

Statera Biopharma is headquartered in Fort Collins, Colorado.

The company's notification from Nasdaq was announced through a press release on GlobeNewswire.

Readers also liked: Instant Payment Notification

The Executive Committee of Statera Biopharma, Inc. is responsible for making key decisions and overseeing the company's direction.

Christopher Zosh is the CEO, or Chief Executive Officer, of the company, a role he has held since January 12, 2019. He is 49 years old.

James Mendolera is the CTO, or Chief Tech/Sci/R&D Officer, and has been in this position since January 2, 2021.

Allie Lopez also serves as the CTO, having taken on the role on January 7, 2020.

Robert W. Buckheit is another CTO, and he started in this position on July 27, 2021. He is 64 years old.

The company's General Counsel is George Wagner, who began his role on November 1, 2021.

Here is a list of the Executive Committee members:

Statera Biopharma's shares are surging today due to a significant development. The company has entered into a non-binding term sheet with Immune Therapeutics Inc to sell its naltrexone and met-enkephalin rights.

This transaction is contingent on further negotiations and agreements, but it's a major step forward for the company.

Statera Biopharma has signed a non-binding letter of intent with Worksite Labs to explore a merger.

The merger aims to enhance shareholder value and operational performance by aligning Statera's goals with Worksite Labs' diagnostic services.

Worksite Labs generated over $50 million in revenues in 2022, and the company aims to leverage capital markets for accelerated growth.

Completion of the merger is contingent upon due diligence, definitive agreements, and necessary approvals.

Both companies are optimistic about the benefits this combination could bring to their operations and market positioning.

Statera Biopharma Inc's shares are surging today due to a non-binding term sheet with Immune Therapeutics Inc.

The transaction involves the sale of Statera's naltrexone and met-enkephalin rights, which is contingent on further negotiations.

Statera Biopharma Inc is listed on the NASDAQ under the ticker symbol STAB, while Immune Therapeutics Inc is listed on the OTC under the ticker symbol IMUN.

This development is a significant event in the market, with investors taking notice of the potential deal.

Statera Biopharma has made significant advancements with its STAT-200 platform. This proprietary composition is a key area of focus for the company.

ImQuest, a Statera company, is collaborating with MolSoft to investigate new, optimized compositions based on the STAT-200 platform. These compositions incorporate desirable elements of STAT-200.

The STAT-200 platform is a crucial part of Statera's research and development efforts.